Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Geoffrey Liu

Showing results (361-370 of 574) with videos related to

Pageof 58
Sort By:
Cancer Medicine|February 13, 2014
Two BRM promoter insertion polymorphisms increase the risk of early-stage upper aerodigestive tract cancersKit Man Wong, Xiaoping Qiu, Dangxiao Cheng, et al.
Lung Cancer (Amsterdam, Netherlands)|September 24, 2022
EGFR mutation prevalence, real-world treatment patterns, and outcomes among patients with resected, early-stage, non-small cell lung cancer in CanadaM Sara Kuruvilla, Geoffrey Liu, Iqra Syed, et al.
Cancer|April 17, 2015
The role of second-hand smoke exposure on smoking cessation in non-tobacco-related cancersLawson Eng, Xin Qiu, Jie Su, et al.
Future Oncology (London, England)|March 6, 2023
TRUST-II: a global phase II study of taletrectinib in <i>ROS1</i>-positive non-small-cell lung cancer and other solid tumorsMisako Nagasaka, Yuichiro Ohe, Caicun Zhou, et al.
Future Oncology (London, England)|June 12, 2023
Plain language summary of the updated results from the CROWN study comparing lorlatinib with crizotinib in people with advanced non-small-cell lung cancerBenjamin J Solomon, Todd M Bauer, Tony S K Mok, et al.
Cancer Medicine|January 25, 2025
Patterns of Treatment and Real-World Outcomes of Patients With Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations Receiving Mobocertinib: The EXTRACT StudyGeoffrey Liu, Shi Feng Nyaw, Tony S K Mok, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 8, 2019
Organoid Cultures as Preclinical Models of Non-Small Cell Lung CancerRuoshi Shi, Nikolina Radulovich, Christine Ng, et al.
Journal of Geriatric Oncology|March 15, 2020
Age differences in patterns and confidence of using internet and social media for cancer-care among cancer survivorsLawson Eng, Jackie Bender, Katrina Hueniken, et al.
The Lancet. Respiratory Medicine|December 19, 2022
Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN studyBenjamin J Solomon, Todd M Bauer, Tony S K Mok, et al.
JTO Clinical and Research Reports|June 9, 2025
Health Utility and Symptom Scores in Patients With Advanced Malignant Pleural Mesothelioma Treated in a Real-World SettingAbhenil Mittal, Louis Everest, Devalben Patel, et al.
Pageof 58

Showing results (361-370 of 574) with videos related to

Sort By:
Pageof 58
Cancer Medicine|February 13, 2014
Two BRM promoter insertion polymorphisms increase the risk of early-stage upper aerodigestive tract cancersKit Man Wong, Xiaoping Qiu, Dangxiao Cheng, et al.
Lung Cancer (Amsterdam, Netherlands)|September 24, 2022
EGFR mutation prevalence, real-world treatment patterns, and outcomes among patients with resected, early-stage, non-small cell lung cancer in CanadaM Sara Kuruvilla, Geoffrey Liu, Iqra Syed, et al.
Cancer|April 17, 2015
The role of second-hand smoke exposure on smoking cessation in non-tobacco-related cancersLawson Eng, Xin Qiu, Jie Su, et al.
Future Oncology (London, England)|March 6, 2023
TRUST-II: a global phase II study of taletrectinib in <i>ROS1</i>-positive non-small-cell lung cancer and other solid tumorsMisako Nagasaka, Yuichiro Ohe, Caicun Zhou, et al.
Future Oncology (London, England)|June 12, 2023
Plain language summary of the updated results from the CROWN study comparing lorlatinib with crizotinib in people with advanced non-small-cell lung cancerBenjamin J Solomon, Todd M Bauer, Tony S K Mok, et al.
Cancer Medicine|January 25, 2025
Patterns of Treatment and Real-World Outcomes of Patients With Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations Receiving Mobocertinib: The EXTRACT StudyGeoffrey Liu, Shi Feng Nyaw, Tony S K Mok, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 8, 2019
Organoid Cultures as Preclinical Models of Non-Small Cell Lung CancerRuoshi Shi, Nikolina Radulovich, Christine Ng, et al.
Journal of Geriatric Oncology|March 15, 2020
Age differences in patterns and confidence of using internet and social media for cancer-care among cancer survivorsLawson Eng, Jackie Bender, Katrina Hueniken, et al.
The Lancet. Respiratory Medicine|December 19, 2022
Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN studyBenjamin J Solomon, Todd M Bauer, Tony S K Mok, et al.
JTO Clinical and Research Reports|June 9, 2025
Health Utility and Symptom Scores in Patients With Advanced Malignant Pleural Mesothelioma Treated in a Real-World SettingAbhenil Mittal, Louis Everest, Devalben Patel, et al.
Pageof 58